Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm multicenter phase III study of CM310 in adolescents with atopic dermatitis (extension study)
CTR20241724Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started May 2024; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20241724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241724.